• First specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to gain CHMP positive opinion¹
• Positive opinion is based on clinical trial results which showed that idarucizumab reverses the anticoagulant effect of dabigatran within minutes^2-4

INGELHEIM, Germany -- (BUSINESS WIRE) --

Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of idarucizumab (to be marketed as Praxbind^®).¹ Idarucizumab is intended for use in adult patients treated with Pradaxa^® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery / urgent procedures or in life-threatening or uncontrolled bleeding.¹

“The CHMP positive opinion in favour of idarucizumab approval is an important recommendation in the field of anticoagulation care,” said Professor Fausto J. Pinto, University of Lisbon, Portugal, and President of the European Society of Cardiology. “The introduction of non-vitamin K antagonist oral anticoagulants, or NOACs, already marked a significant advancement in anticoagulation care. The approval of specific reversal agents to stop their anticoagulant effect immediately when needed will be the next advancement.”

“This will be the icing on the cake for treating our stroke patients with anticoagulants like dabigatran: in an emergency we will be able to switch off their treatment almost instantly, and safely. This will make treatment choices much easier for both doctor and patient,” stated Professor Kennedy R. Lees, University of Glasgow, UK, and President of the European Stroke Organisation.

The CHMP positive opinion was based on data from healthy volunteers, as well as results from an interim analysis of the RE-VERSE AD™ trial.^2-5 In the studies, the reversal effects of idarucizumab were evident immediately, within minutes after administration of 5 grams of idarucizumab.^2-4 Reversal was complete and sustained in almost all patients.^2-5 No serious adverse events considered causally related to idarucizumab were identified.^2-5 Additionally, no pro-coagulant effect was observed after the administration of idarucizumab.^2,5

“Our scientists have worked intensively on idarucizumab for years, so we are now very excited about this recommendation for European approval”, said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “I am convinced that the availability of idarucizumab will give physicians and patients added assurance in choosing dabigatran as the first ever NOAC with a specific reversal agent.”

Idarucizumab is currently being reviewed for approval by regulatory authorities worldwide⁶, including the U.S. FDA⁷. Boehringer Ingelheim plans to submit idarucizumab in all countries where dabigatran is licensed.⁶

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

~ENDS~

Please click on the link below for ‘Notes to Editors’ and References’:
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/25_september_2015_pradaxa.html

View source version on businesswire.com: http://www.businesswire.com/news/home/20150925005273/en/

CONTACT:

Boehringer Ingelheim GmbH
Friederike Middeke
Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail: press@boehringer-ingelheim.com
Twitter: http://twitter.com/Boehringer
or
More information
www.boehringer-ingelheim.com